Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717756 | 0.95 | NPC1 (0.41) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717574 | 0.89 | NPC1 (0.47) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717687 | 0.89 | NPC1 (0.42) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717796 | 0.82 | SCN5A (0.48) | NPC1RAB9ASCN5AKCNH2SCN9A | |
| SCHEMBL13717969 | 0.82 | NPC1 (0.43) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717929 | 0.81 | AURKA (0.44) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717441 | 0.80 | MCHR1 (0.47) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717387 | 0.80 | MCHR1 (0.45) | NPC1RAB9AMITFPKMKMT2A | |
| SCHEMBL13717480 | 0.79 | AURKA (0.52) | MCHR1NPBWR1CHRM5AURKAGRK2 | |
| SCHEMBL13717668 | 0.79 | MCHR1 (0.44) | NPC1RAB9AMITFPKMSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | claimed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | claimed |
| US-20150329558-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-11-19 | — | — | US | claimed |
| EP-2707361-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | claimed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20140329755-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE | GILEAD SCIENCES, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2707361-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | NPC1 1180/4885RAB9A 1191/4885MITF 3671/4885 |
| US-20150329558-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | NPC1 1180/4885RAB9A 1191/4885MITF 3671/4885 |
| US-20140329755-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ARRHYTHMIAS OR HEART FAILURE | CAMKK2, CAMK4, CAMK1 | NPC1 3730/4885RAB9A 4126/4885MITF 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.